Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Total Current Liabilities (2016 - 2025)

Ironwood Pharmaceuticals' Total Current Liabilities history spans 16 years, with the latest figure at $242.2 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 523.53% year-over-year to $242.2 million; the TTM value through Dec 2025 reached $242.2 million, up 523.53%, while the annual FY2025 figure was $242.2 million, 523.53% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $242.2 million at Ironwood Pharmaceuticals, roughly flat from $242.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $305.4 million in Q2 2023 and bottomed at $23.3 million in Q2 2022.
  • The 5-year median for Total Current Liabilities is $140.0 million (2021), against an average of $136.3 million.
  • The largest annual shift saw Total Current Liabilities soared 1210.8% in 2023 before it plummeted 85.93% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $161.7 million in 2021, then plummeted by 84.21% to $25.5 million in 2022, then soared by 981.69% to $276.1 million in 2023, then tumbled by 85.93% to $38.8 million in 2024, then skyrocketed by 523.53% to $242.2 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Total Current Liabilities are $242.2 million (Q4 2025), $242.5 million (Q3 2025), and $232.5 million (Q2 2025).